Chronic thromboembolic and pulmonary arterial hypertension share acute vasoreactivity properties

Chest

Volumn 130, Issue 3, 2006, Pages 841-846

  Ulrich, Silvia ^a   Fischler, Manuel ^a   Speich, Rudolf ^a   Popov, Vladimir ^b   Maggiorini, Marco ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Clinic of Pulmonary Medicine and Rehabilitation   (Switzerland)

Author keywords

Chronic thromboembolic pulmonary hypertension; Pulmonary arterial hypertension; Pulmonary hemodynamics; Pulmonary vascular compliance; Vasoreactivity testing

Indexed keywords

ILOPROST; NITRIC OXIDE; VASODILATOR AGENT;

ADULT; ARTERY COMPLIANCE; ARTICLE; BLOOD VESSEL REACTIVITY; CALCULATION; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; DEATH; DIASTOLIC BLOOD PRESSURE; FEMALE; HEART CATHETERIZATION; HEART RIGHT VENTRICLE FAILURE; HUMAN; INHALATION; LUNG HEMODYNAMICS; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULSE PRESSURE; SWAN GANZ CATHETER; SYSTOLIC BLOOD PRESSURE; THROMBOEMBOLISM;

EID: 33748863750     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.130.3.841     Document Type: Article

References (38)

1. Weir EK, Rubin LJ, Ayres SM, et al. The acute administration of vasodilators in primary pulmonary hypertension: experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. Am Rev Respir Dis 1989; 140:1623-1630
2. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70:580-587
3. Palevsky HI, Schloo BL, Pietra GG, et al. Primary pulmonary hypertension: vascular structure, morphometry, and responsiveness to vasodilator agents. Circulation 1989; 80:1207-1221
4. Nakayama Y, Nakanishi N, Sugimachi M, et al. Characteristics of pulmonary artery pressure waveform for differential diagnosis of chronic pulmonary thromboembolism and primary pulmonary-hypertension. J Am Coll Cardiol 1997; 29:1311-1316
5. Castelain V, Chemla D, Humbert M, et al. Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension. Am J Respir Crit Care Med 2002; 165:338-340
6. Moser KM, Bloor CM. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest 1993; 103:685-692
7. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347:322-329
8. Ghofrani HA, Schermuly RT, Rose F, et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2003; 167:1139-1141
9. Nagaya N, Shimizu Y, Satoh T, et al. Oral beraprost sodium improves exercise capacity and ventilatory efficiency in patients with primary or thromboembolic pulmonary hypertension. Heart 2002; 87:340-345
10. Castelain V, Herve P, Lecarpentier Y, et al. Pulmonary artery pulse pressure and wave reflection in chronic pulmonary thromboembolism and primary pulmonary hypertension. J Am Coll Cardiol 2001; 37:1085-1092
11. Sitbon O, Brenot F, Denjean A, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension: a dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 1995; 151:384-389
12. Raffy O, Azarian R, Brenot F, et al. Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. Circulation 1996; 93:484-488
13. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43(suppl):40S-47S
14. Rich S, Kaufmann E, Lew PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327:76-81
15. Leuchte HH, Schwaibhnair M, Baumgartner RA, et al. Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. Chest 2004; 125:580-586
16. Jolliet P, Bulpa P, Thorens J-B, et al. Nitric oxide and prostacyclin as test agents of vasoreactivity in severe precapillary pulmonary hypertension: predictive ability and consequences on haemodynamics and gas exchange. Thorax 1997; 52:369-372
17. Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126(suppl):35S-62S
18. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary hypertension. Circulation 2005; 111:3105-3111
19. Sitbon O, Humbert M, Jagot JL, et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998; 12:265-270
20. Hoeper MM, Olschewski H, Ghofrani HA, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. J Am Coll Cardiol 2000; 35:176-182
21. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999; 99:1858-1865
22. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43(suppl):5S-12S
23. Williamson DJ, Hayward C, Rogers P, et al. Acute hemodynamic responses to inhaled nitric oxide in patients with limited scleroderma and isolated pulmonary hypertension. Circulation 1996; 94:477-482
24. Pietra GG, Capron F, Stewart S, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004; 43(suppl):25S-32S
25. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43(suppl):13S-24S
26. Williamson TL, Kim NH, Rubin LJ. Chronic thromboembolic pulmonary hypertension. Prog Cardiovasc Dis 2002; 45:203-212
27. Egermayer P, Peacock AJ. Is pulmonary embolism a common cause of chronic pulmonary hypertension? Limitations of the embolic hypothesis. Eur Respir J 2000; 15:440-448
28. Kim H, Yung GL, Marsh JJ, et al. Pulmonary vascular remodeling distal to pulmonary artery ligation is accompanied by upregulation of endothelin receptors and nitric oxide synthase. Exp Lung Res 2000; 26:287-301
29. Fedullo PF, Rubin LJ, Kerr KM, et al. The natural history of acute and chronic thromboembolic disease: the search for the missing link. Eur Respir J 2000; 15:435-437
30. Colorio CC, Martinuzzo ME, Forastiero RR, et al. Thrombophilic factors in chronic thromboembolic pulmonary hypertension. Blood Coagul Fibrinolysis 2001; 12:427-432
31. Wolf M, Rover-Neumann C, Parent F, et al. Thrombotic risk factors in pulmonary hypertension. Eur Respir J 2000; 15:395-399
32. Moser KM, Fedullo PF, Finkbeiner WE, et al. Do patients with primary pulmonary hypertension develop extensive central thrombi? Circulation 1995; 91:741-745
33. McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126(suppl):14S-34S
34. Fedullo PF, Auger WR, Kerr KM, et al. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001; 345:1465-1472
35. Olschewski H, Rose F, Grunig E, et al. Cellular pathophysiology and therapy of pulmonary hypertension. J Lab Clin Med 2001; 138:367-377
36. Trell E, Lindstrom C. Primary and chronic thromboembolic pulmonary hypertension: clinical and pathoanatomic observations. Acta Med Scand Suppl 1972; 534:1-30
37. McLaughlin W, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106:1477-1482
38. Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000; 342:1866-1870